The PI3K/mTOR signaling cascade is fundamental in T-cell activation and fate decisions. We showed the distinct regulation of PI3K/mTOR in regulatory and effector T-cells and proposed the potential therapeutic benefit of targeting this pathway to control the balance between effector and regulatory T-cell activities. Substantial adverse effects in long-term clinical usage of rapamycin suggest the use of alternative treatments in restraining effector T-cell function in transplant patients. We hypothesize that dual PI3K/ mTOR inhibitors may represent an immunosuppressant alternative. Here we show that dual PI3K/mTOR PI-103 and PKI-587 inhibitors interfered IL-2-dependent responses in T-cells. However, in contrast to the inhibitory effects in non-Treg T-cell proliferation and effector functions, dual inhibitors increased the differentiation, preferential expansion, and suppressor activity of iTregs. Rapamycin, PI-103, and PKI-587 targeted different signaling events and induced different metabolic patterns in primary T-cells. Similar to rapamycin, in vivo administration of PI-103 and PKI-587 controlled effectively the immunological response against allogeneic skin graft. These results characterize specific regulatory mechanisms of dual PI3K/ mTOR inhibitors in T-cells and support their potential as a novel therapeutic option in transplantation.
Introduction
Standard therapeutic strategies in preventing allograft rejection include immunosuppressive regimens that rely on the nonspecific depletion or inhibition of Tcell responses. Despite dramatic increases in first-year graft survival rates, chronic allograft dysfunction remains a major challenge in transplantation [1] [2] [3] . In this context, a growing body of evidence recognizes the suppressive activity of Treg cells [4] [5] [6] [7] and, specifically, the balance between graft-reactive effector cells and graft-protective suppressor Tregs, as the ultimate determinant of long-term allograft survival [8] [9] [10] .
Clinical and experimental studies support the therapeutic potential of targeting the mTOR pathway in transplant patients as a critical regulator of the balance between regulatory and effector T-cells [11] [12] [13] [14] . However, serious adverse effects of long-term use of rapamycin [15, 16] , the prototypical mTOR inhibitor in clinical transplantation, have fueled the development of alternative options for the efficient and safe targeting of mTOR-dependent activity in T-cells. The development of pharmacological inhibitors of multiple targets within the PI3K/AKT/mTOR pathway may represent a valid alternative, but their clinical implementation in the transplant field requires further investigation.
In the present study, we explored the effects and mechanisms of action of dual PI3K/mTOR inhibitors PI-103, a pyridinyl-furano-pyrimidine with a high degree of selectivity for class-IA PI3K and mTORC1 [17] , and PKI-587, a novel inhibitor of class-IA PI3K, mTORC1 and mTORC2. Our group and others have reported the inhibitory properties of these two compounds against cancer cell growth [18] [19] [20] [21] [22] but, to date, the immunoregulatory potential of these drugs has not yet been explored. In this study, we have compared the effects of these dual PI3K/mTOR inhibitors to rapamycin in vitro and in vivo on the regulation of T-cell phenotype, function and fate choices in primary human and mouse T-cells. The results establish a solid experimental base to support the potential therapeutic benefit of dual PI3K/mTOR inhibitors in clinical transplantation.
Materials and methods
The description of materials methods and statistical analyses is detailed in (Appendix S1).
Results

Dose-limiting toxicity of dual PI3K/mTOR inhibitors on primary human T-cell culture
The goal of the initial set of experiments was to identify the highest effective dose of dual inhibitors PKI-587 and PI-103 that did not cause significant loss of cell viability in 4-day T-cell culture with anti-CD3 (OKT3) and IL-2. The results demonstrated that 400 nM of PI-103 and 80 nM of PKI-587 were the highest doses tolerated by primary T-cells in culture without altering the cell viability (Fig. 1a) . Rapamycin at 100 nM and 20 nM as standard optimal and low concentration ranges, respectively, did not produce any significant decrease in cell viability either. We therefore established the low and high working doses of the drugs throughout the study as 20 nM and 100 nM for rapamycin, 80 nM and 400 nM for PI-103, and 16 and 80 nM for PKI-587, respectively. Addition of these concentrations of drugs in the cell culture did not induce any significant increase on the expression levels of active Caspase-3 or Annexin V in T-cells (Fig. 1b and c) .
Reduction of early T-cell activation by PI3K/mTOR inhibition
We assessed the effects of rapamycin, PI-103, and PKI-587 on the expression of the early activation markers CD69 and CD25 (the IL-2-R-alpha subunit). After 18-h activation of primary na€ ıve human CD4 + T-cells with OKT3 and anti-CD28, approximately 20% of cells expressed high levels of CD69. Addition of inhibitors did not induce any significant change in the percentages of CD69 + cells (Fig. 2a) . However, unlike CD69, the percentages of T-cells expressing high levels of CD25 were consistently reduced in the presence of either rapamycin or dual inhibitors ( Fig. 2a and b) .
Reduced IL-2 production in human T-cells by PI-103
We next measured the IL-2 produced by na€ ıve T-cells cultured in OKT3/anti-CD28-containing medium for 40 h in the presence or not of rapamycin, PI-103, and PKI-587. The addition of drugs at high doses inhibited IL-2 production (Fig. 2c) . When we examined the functional link between IL-2 producing and responding cells, we observed a significant reduction in CD25 expression on IL-2 + cells in all pharmacologically treated T-cell cultures compared to untreated-control cells (Fig. 2d) , supporting the notion that drug-treated, IL-2-producing cells cannot efficiently respond to IL-2.
Decreased human T-cell proliferation caused by PI3K/ mTOR inhibition
We next assessed the impact of rapamycin, PI-103, and PKI-587 on the proliferation of CFSE-labeled CD4 + T-cells activated with OKT3 and anti-CD28 for 5 days.
As expected, all compounds produced a substantial reduction in the proliferative response (Fig. 2e) , although quantitative and qualitative differences were observed among the drugs. The effect of rapamycin was not dose-related, as low (20 nM) and high (100 nM) in T-cells after 18-h culture with OKT3 and anti-CD28 in the absence (Control) or in the presence of rapamycin, PI-103, or PKI-587 at the indicated doses. Distribution in percentages of CD69-and CD25-expressing cells is indicated inside the panels. (b) Mean AE SD of pooled data collected from three independent experiments for CD25 expression are depicted with respect to control conditions. (c) Supernatants from T-cells cultured for 40 h in antiCD3 + anti-CD28-media in the absence (Control) or in the presence of rapamycin, PI-103, or PKI-587 were collected, and the IL-2 produced was measured by ELISA. (d) The expression of CD25 was evaluated in IL-2-producing T-cells after 18-h culture with OKT3 and anti-CD28 in the absence (Control) or in the presence of rapamycin, PI-103, or PKI-587 at the indicated doses. We demonstrated in early studies that primary human na€ ıve CD4 + T-cells differentiate into suppressor Tregs in the presence of TGF-ß and IL-2 only after undergoing multiple rounds of cell division [25] [26] [27] . In light of our results, we questioned whether the antiproliferative action of rapamycin and dual inhibitors was compatible with the IL-2-dependent differentiation of na€ ıve T-cells into iTregs. Our results confirmed the ability of rapamycin to improve the differentiation of Tregs as previously reported [11] [12] [13] and revealed that both PI-103 and PKI-587 exert similar increasing effects on iTreg differentiation and that the resulting Treg cells display enhanced suppressive function (Fig. 3a-c , and S1b). The acquisition of Treg phenotype by T-cells cultured in the presence of rapamycin or dual inhibitors started at earlier cell divisions than homologous cells in iTreg medium alone (Fig. 3b) . Therefore, the sequence of cell expansion followed by cell differentiation during iTreg fate determination is abrogated, and the presence of these drugs eliminates the requirement of multiple rounds of cell divisions before acquiring the Treg phenotype and promotes the early accumulation of FoxP3 + -iTreg cells. In addition, Treg cells are more resistant to the antiproliferative effects of drugs compared to activated (CD25 + ) non-Treg T-cells (Fig. 3d) , which further contributes to the predominance of the Treg population among the drug-treated T-cells. The FOXP3 gene is the master regulator of the Treg gene expression program and its constitutive expression is required for Treg-suppressive function [28] . Methylation of CpG dinucleotides at the highly conserved TSDR region of the FOXP3 locus represses FoxP3 expression, and their demethylation correlates with stable FoxP3 expression [29] . The methylation levels across the nine CpG sites of the TSDR in freshly sorted natural Tregs were 30.2 AE 3.6% (n = 9) and in CD4 + na€ ıve T-cells increased to 89.3 AE 0.9% (n = 12). Our data analysis on iTreg cells generated from na€ ıve CD4 + T-cells and maintained in culture for 8 days showed methylation levels of 50.3 AE 4.8% (n = 5). The presence of rapamycin (41.5 AE 4.6, n = 5), PI-103 (43.8 AE 5.7, n = 5), and PKI-587 (37.4 AE 4.4, n = 4) showed a similar trend toward higher demethylation compared to control iTreg conditions, although the effects of PI-103 were not significant. Addition of drugs to the cell culture resulted in the substantial reduction of IL-17-producing/RORct + [30] cells ( Fig. 3e and S1c). Taken together, our results support the notion that rapamycin and dual inhibitors drive the plasticity of T-cell responses toward the prevalence of the regulatory activity by increasing iTreg differentiation, function and stability, and by reducing the expansion and differentiation of the effector T-cell population.
PI3K/mTOR signaling modulated by PI-103 and PKI-587
To investigate specific signaling events by which rapamycin or dual inhibitors may regulate iTreg differentiation, we assessed the expression of several key components of the AKT-mTOR signaling pathway by Western Blot analysis. The inclusion of rapamycin induced a robust dose-dependent attenuation of the phosphorylation of AKT at Serine-473, a requirement to achieve the stable, full activated state of AKT [31] (Fig. 4) . The results across the different conditions tested also showed a strong positive correlation between phospho-AKT levels and phospho-GSK3b at Serine-9, a downstream target of AKT [32] . There is a general consensus that Serine-473 of AKT is specifically phosphorylated by mTORC2 [33] . Accordingly, the low levels of phosphorylated AKT would imply the inhibitory action of prolonged rapamycin treatment to mTORC2 activity as reported [16] . Rapamycin-treated cells also displayed reduced mTORC1 signaling as evidenced by low phosphorylation levels of the translational repressor 4EBP1 at Threonines 37 and 46. A similar pattern resulted from the action of PI-103 at low dose (80 nM), with reduced phospho-AKT and phospho-GSK3b levels and a limited decline in phospho-4EBP1 levels. However, at higher doses, PI-103 elicited a substantial increase in the phosphorylated forms of AKT and GSK3b above control levels. In contrast, PKI-587, even at the lowest concentrations (16 nM) completely abrogated the phosphorylation of 4EBP1 and induced a concurrent large increase in phospho-AKT and phosho-GSK3b levels. Unlike rapamycin and PI-103, PKI-587 treatment also altered ERK1/2 signaling. The phosphorylation pattern of mTOR at Serines 2448 and 2481 did not directly correlate with mTORC1 and mTORC2 activities ( 
PI3K/mTOR inhibition modulates IL-2 dependent metabolic profile
Our group and others have reported the cell metabolic switch during the transition from na€ ıve to iTreg cells and the fundamental role of the PI3K-AKT-mTOR signaling cluster in this process [26, [37] [38] [39] .To evaluate the effects of PI3K/mTOR inhibitors on the bioenergetic status of the T-cells, we measured oxygen consumption rates (OCR, a measure of mitochondrial respiration) and extracellular acidification rates (ECAR, an indicator of glycolytic cell function). As expected in the early phase of iTreg differentiation (2 day-culture), T-cells in iTreg medium still demonstrated a predominant aerobic glycolytic metabolism and thus ECAR measurements were more sensitive to the metabolic stress induced by drugs. Rapamycin-treated T-cells exhibited the most prominent reductions in ECAR, whereas the effects induced by PI-103 and PKI-587, although less prominent, did also caused significant reduction in the glycolytic rates compared to untreated (control) cells ( Fig. 5 panels a, c, d , and g). After 7 days in iTreg medium, all cells in culture exhibited a metabolic switch toward a less glycolytic profile (Fig. 5b , c, and g), which is known to be a common metabolic signature of Tregs [38, 39] . In this late phase of iTreg differentiation, we found a significant reduction of OCR in all drug-treated T-cells (Fig. 5 , panels e, f, and g). However, qualitative differences emerged among treatments regarding the type of substrate used to fuel mitochondrial respiration.
In fact, addition of Etomoxir (a specific inhibitor of fatty acid oxidation -FAO-) demonstrated that while all drug treatments lowered FAO-related OCR, only rapamycin-treated cells improved significantly non-FAO to partially compensate the reduced utilization of fatty acids. In contrast, only PI-103-treatment caused also a decrease in non-FAO rates. Our results suggest that the distinct signaling events targeted by rapamycin, PI-103, or PKI-587 may influence different kinetics and pathways implicated in the metabolic reprogramming of T-cells. However, after 7 days in culture, the resultant metabolic profile is similar in all drug treatments. Therefore, in spite of the specific mechanisms of action, the bioenergetic changes induced by rapamycin, PI-103, or PKI-587 share a common shift toward a cell metabolic state optimally suited to differentiate into functional Treg cells.
Administration of PI3K/mTOR inhibitors in vivo alters T-cell subset distribution and activation
Because the development, regulation, and function of T-cells differ between mice and human [40-43], we first verified the suppressive potential of rapamycin, PI-103, and PKI-587 in vitro in mouse T-cells on CD25 expression, IL-2 production and proliferative responses (Fig. S3) . However, unlike the response in human primary T-cells, we did not detect any significant alteration in the expression of CD69 (Fig. S3a) . Our next set of experiments was aimed at the evaluation of the effects of in vivo administration of dual PI3K/mTOR inhibitors compared to those evoked by rapamycin or vehicle control. Fourteen days after the first treatment, the animals were sacrificed, spleens removed and CD4 + T-cells isolated for analysis. The total number of lymphocytes in the spleens of drug-treated mice were unchanged (1.37 x 10 7 AE 0.27, n = 7, in control; 1.31 x 10 7 AE 0.18, n = 8, in rapamycin, 1.22 x 10 7 AE 0.21, n = 6, in PI-103, and 1.28 x 10 7 AE 0.21, n = 7, in PKI-587). The analyses of T-cells showed also similar CD4/CD8 ratios, although the frequency of CD4 + and CD8 + T-cells was higher in PI-103 mice compared to control (Fig. 6a) (Fig. S4) . Next, we asked whether the reduced population of antigen-experienced T-cells was associated with the inability of in vivo drugtreated cells to respond to the TCR/CD28 costimulation. To the same extent as the in vitro-treated T-cells, the in vivo treatment with rapamycin, PI-103, or PKI-587 rendered T-cells unable to adequately upregulate the early expression of CD25 (Fig. 6b , top panel) and to induce a proliferative response (Fig. 6c) . However, unlike the in vitro results, the expression of CD69 was also significantly reduced, suggesting that the in vivo effects of drugs may partially rely on indirect environmental variables that alter the capacity of T-cells to achieve full activation. Interestingly, although, the inhibitory effects induced by rapamycin and PI-103 on the expression of CD25 and CD69 were only transient, as an extended period of activation (30 h) normalized the expression of both activation markers to the levels of the control untreated group. In contrast, the in vivo treatment with PKI-857 poised the T-cell population to a less-responsive state (Fig. 6b, bottom panels) . IL-2 production also showed substantial differences from the in vitro culture with the drugs, and only the T-cells isolated from animals treated with PKI-587 showed a significant reduction in IL-2 production (Fig. 6d) . We next examined whether the in vivo treatments skewed the susceptibility of CD4 + T-cells to differentiate toward a regulatory or an inflammatory phenotype. Rapamycin and PKI-587 treatments promoted the differentiation of T-cells into iTregs and inhibited the progression to effector TH17 (Fig. 6e-g ). However, the PI-103 treatment was ineffective altering the generation of iTregs and only reduced the polarization into effector TH17. Similar to in vitro experiments, these results demonstrated that the in vivo treatments with rapamycin, PI-103, and PKI-587 can prime CD4 + T-cell lineage differentiation by altering the sensitivity of the cells to express FoxP3 or RORct and determining whether CD4 + T-cells adopt the Treg or the effector TH17 fate, respectively.
Administration of PI3K/mTOR inhibitors in vivo modulates the response against allograft
We used MHC-mismatched skin from BALBc mouse grafted onto C57BL/6 recipients to evaluate the effect of dual PI3K/mTOR inhibition in vivo. Kaplan-Meier plots illustrated the significant increase in allograft survival in all group of mice treated with drugs (Fig. 7, top panels) . Histology of the skin allografts in control mice analyzed on day 12 post-transplant (Fig. 7 , bottom panels) revealed a prominent necrotic cuticular layer of the skin graft and abundant inflammatory cell infiltration, ranked as grade IV according to the Zdichavsky classification [44] . In contrast, the rapamycin, PI-103, and PKI-587 groups did not exhibit any necrotic tissue and the skin graft was well integrated. Only mild dermal inflammation without vasculitis, folliculitis, or epidermal degeneration was seen, compatible with grade I allograft rejection.
Discussion
Our results with primary human na€ ıve CD4 + T-cells illustrate a potential mechanism of action of rapamycin and dual inhibitors in early stages of T-cell activation by interrupting the positive feedback loop between IL-2 and IL-2-R signaling at two different levels: One through the very sensitive regulation of CD25 expression, and a second through the regulation of IL-2 production. In control conditions cells that produced IL-2 also co-expressed high levels of CD25, but this ligandreceptor co-expression was lost in the presence of drugs. In addition, the proliferative response of T-cells in response to CD3/TCR engagement demonstrated similar patterns of sensitivity to the drugs regardless the addition of exogenous IL-2 or the costimulation with anti-CD28. These findings suggest the prevalence of a common IL-2-dependent control of T-cell expansion as proposed in other studies [23, 45] , although we cannot rule out the contribution of mTOR-mediated IL-2-independent proliferation in TCR/CD28-engaged T-cells [23, 24] . The fact that the IL-2-R of intermediate affinity expressed in the absence of CD25 is still fully functional to respond to IL-2 (albeit less efficient) may explain the reduced but not abrogated proliferative response in drug-treated cells.
Like rapamycin [11] [12] [13] , dual PI3K/mTOR inhibitors PI-103 and PKI-587 promoted the differentiation of primary human na€ ıve T-cells into FoxP3 + -iTreg suppressor cells. Early work from our group characterized the transition into functional iTregs as a tightly regulated and sequential process. This occurs in response to weak TCR stimulation in the presence of IL-2 and TGF-b only after the cell undergoes several rounds of cell division, and it entails a fine-tuned reconfiguration of the PI3K/AKT/mTOR pathway [25] [26] [27] . This is consistent with the "two-step differentiation model" proposed by Guo et al. [46] . According to this model the initial TCR-dependent conditioning induces the expression of CD25 and "primes" the cell to efficiently respond to the "cytokine-dependent" acquisition of the Treg phenotype. In this study, the presence of rapamycin, PI-103, or PKI-587 promoted the differentiation of iTregs without requiring multiple rounds of cell division. Under suboptimal TCR stimulation, IL-2 may transduce STAT5-dependent signals needed to induce FoxP3 expression [47] . In combination with STAT-5, TGF-b signaling through Smad3 plays a major role in the regulation of FoxP3 and CD25 expression [48, 49] . We can speculate that, in the presence of rapamycin and dual inhibitors, the weak IL-2-R signaling in conjunction with Smad3 would be sufficient to sustain iTreg differentiation and expansion but not to support the optimal IL-2-dependent expansion of conventional nonTreg cells. Consequently, in agreement with our results ( Fig. 3d) , addition of rapamycin or dual PI3K/mTOR inhibitors in a mixed population of activated T-cells would result in the accumulation of functionally suppressive iTreg cells. mTOR delivers an obligatory signal for proper activation and differentiation of T-cells through two functionally distinct signaling complexes, mTORC1, and mTORC2 [50] . Rapamycin is well known to selectively inhibit mTORC1 in short course treatments, but prolonged exposure leads to reduced mTORC2 activity and a partial rescue of mTORC1 [16, 51] . Our group and others have reported functional mTOR as a crucial regulator of iTreg cell differentiation and suppressor activity [26, 39] . Here, we demonstrated the distinct influence of rapamycin and dual-PI3K/mTOR inhibitors on the mTORC1 and mTORC2 balance during the transition of na€ ıve T-cells to iTregs. Despite inducing similar outcomes in promoting iTreg differentiation and opposing pro-inflammatory effector function, our results clearly establish that single mTOR (rapamycin) and dual PI3K/mTOR inhibitors target different signaling events of the same pathway. The Western Blot results fit with the complex plasticity of the AKT/mTOR signaling reported in other studies [52] [53] [54] [55] [56] , including cross-talks, feedback loops and compensatory mechanisms within the PI3K/AKT/mTOR signaling-cluster and with several other pathways.
The association between cell signaling and metabolism is especially relevant in the regulation of T-cell function. Pro-inflammatory effector responses rely mostly on glycolysis to meet their energy demands; conversely, functional Treg cells exhibit higher dependency on mitochondrial oxidative phosphorylation [38, 57, 58] . Therefore, cellular metabolic control is currently envisioned as a novel therapeutic strategy to redirect T-cell function and restore immune homeostasis. Since mTOR is a critical sensor and driver of cell metabolism, the metabolic modulation through the pharmacological targeting of the PI3K/AKT/mTOR pathway may constitute an attractive immunotherapeutic approach to redirect Tcell function, as it is in cancer cells. In our study, addition of rapamycin and dual PI3K/mTOR inhibitors in the culture media resulted in the alteration of the glycolytic pathway. This early antiglycolytic effect and the limited effect of rapamycin and dual inhibitors on mitochondrial respiration would facilitate the metabolic reprogramming toward the prevalence of mitochondrial respiration over glycolysis, a metabolic state that favors iTreg cell differentiation. Our results also revealed the different substrate utilization in mitochondrial respiratory metabolism in rapamycin-treated and dual PI3K/mTOR inhibitor-treated cells as illustrated by their distinct Etomoxir-sensitivity. Overall, our findings uncovered the different metabolic programs induced by rapamycin and dual inhibitors, although all of them drive T-cells toward similar Treg-compatible bioenergetic profile. Additional studies are underway to elucidate the specific signaling events associated with the distinct metabolic alterations and particular effector responses modulated by rapamycin and dual inhibitors. The characterization of fundamental differences between activation of na€ ıve and memory T-cells may also offer new opportunities to tailor more efficient therapeutic interventions. While na€ ıve T-cells require a rapid mTORC1-dependent readjustment of the metabolic machinery toward glycolysis, the glycolytic switch in antigen-experienced cells is more mTORC2-dependent [57] [58] [59] In this context, the mTORC2 prevalence of PI-103-treated cells may be particularly effective in the activation of memory T-cell recall responses. The selective control of these mTORC-specific metabolic T-cell responses may be of the utmost relevance not only in preventing allograft rejection, but also in mediating a protective response against pathogens and tumor growth.
In the field of transplantation, there is an emerging interest in enhancing the suppressor immune response as an alternative strategy to reach a clinical tolerogenic state and preserve long-term graft function [60] [61] [62] [63] [64] . The immunosuppressive action of rapamycin has been already described in different mouse models of transplantation [65] [66] [67] [68] and, in this study, we have characterized the immunomodulatory effects of PI-103 and PKI-587 in Tcells in vitro and in vivo. Our analyses of the skin grafts demonstrated that the in vivo treatment with PI-103 and PKI-587 induced an effective control of the immunological response against allogeneic skin graft, likely by harnessing the activation and effector function of T-cells and, at least for PKI-587, by also priming their differentiation into protective Tregs. Indeed, all in vivo drug treatments reduced the susceptibility of CD4 + T-cells to differentiate toward a pro-inflammatory TH17 effector phenotype. These results are in line with the growing body of literature recognizing the involvement of effector TH17 cells in transplant rejection [69] [70] [71] [72] [73] [74] [75] . We have noted substantial differences on the effects promoted by PI-103 in vitro and in vivo, which may be attributed to the rapid plasma and tissue clearance exhibited by this compound [18] . This study provides the first evidence supporting the potential of dual PI3K/mTOR inhibitors to generate a successful tolerogenic state essential in the prevention of allograft rejection The in vivo treatments with dual PI3K/mTOR inhibitors as well as with rapamycin promoted the skewed differentiation of CD4 + T-cells toward a noninflammatory response, which may define the outcome of the immune reaction toward the increased rates of allograft survival. In addition, we characterized specific cellular, signaling and metabolic mechanisms triggered by dual PI3K/mTOR inhibitors that may control T-cell activation and lineage fate decisions. Further studies are warranted to assess the immunosuppressant efficiency and toxic profile of this family of compounds to confirm their clinical utility in transplantation. 
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article:
Appendix S1. Materials and Methods. Figure S1 . Effects of rapamycin and dual inhibitors on the proliferation and differentiation of human na€ ıve CD4 + T cells. Figure S2 . Effects of rapamycin and dual inhibitors on the expression of mTOR. Figure S3 . Altered activation, proliferation and IL-2 production in in vitro drug-treated mouse T cells. Figure S4 . Phenotype of splenocytes from in vivo drug-treated and control mice. 
